RxDoctor Payments Data

Allison Padegimas, MD

Cardiovascular Disease · Wallingford, CTNPI 1144630328

Payments from drug & device makers

$737in general payments, 2019–2025

Across 38 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$126
  • Novartis$105
  • Pfizer$92
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$57
  • Boston Scientific$48
  • Abiomed$43
  • plus $266 from 11 others

What the payments were for

  • Food & beverage$71998%
  • Entertainment$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$737 in reported general payments places this provider in the 35th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$130,636
Medicare patients
784
Services billed
1,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban182$261,947
Repatha SureclickEvolocumab66$84,699
XareltoRivaroxaban50$67,619
EntrestoSacubitril/Valsartan13$24,729
Praluent PenAlirocumab19$18,562
NexletolBempedoic Acid11$11,975
Metoprolol Succinate345$4,794
Rosuvastatin Calcium200$3,768
Ezetimibe115$2,193
Diltiazem 24hr Er (Cd)Diltiazem Hcl48$1,545
Midodrine Hcl15$1,514
Atorvastatin Calcium149$1,281
Amlodipine Besylate185$1,242
Metoprolol Tartrate88$1,213
Valsartan23$978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$92$261,947182 claims
Johnson & JohnsonXarelto$126$67,61950 claims
NovartisEntresto$105$24,72913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Wallingford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →